Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

Published Date: 13 Sep 2024

Novel agent nearly halved risk of progression as first-line therapy in phase III trial

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High Rate of Deep Remission for Relapsed/Refractory CLL Using Triple Regimen.

2.

Outcomes in Resected Melanoma Influenced by Timing of Recurrence

3.

For incarcerated people, study shows gaps exist in quality of cancer care

4.

Promising for Monitoring and Diagnosis of AD is the finger-prick test.

5.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot